Castle Biosciences Dividend

Dividend criteria checks 0/6

Castle Biosciences does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield	1.7%
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Earnings per share	-US$2.08
Dividend yield forecast in 3Y	n/a

Recent dividend updates

No updates

Recent updates

Investors Appear Satisfied With Castle Biosciences, Inc.'s (NASDAQ:CSTL) Prospects

Jan 27

Castle Biosciences (NASDAQ:CSTL) Is In A Good Position To Deliver On Growth Plans

Oct 31

Earnings Working Against Castle Biosciences, Inc.'s (NASDAQ:CSTL) Share Price Following 36% Dive

Jun 13

Analysts Just Published A Bright New Outlook For Castle Biosciences, Inc.'s (NASDAQ:CSTL)

Aug 14

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if CSTL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CSTL's dividend payments have been increasing.

Dividend Yield vs Market

Castle Biosciences Dividend Yield vs Market

How does CSTL dividend yield compare to the market?
Segment	Dividend Yield
Company (CSTL)	n/a
Market Bottom 25% (US)	1.5%
Market Top 25% (US)	4.7%
Industry Average (Healthcare)	1.7%
Analyst forecast in 3 Years (CSTL)	n/a

Notable Dividend: Unable to evaluate CSTL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CSTL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate CSTL's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as CSTL has not reported any payouts.

Discover strong dividend paying companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Castle Biosciences Dividend

Dividend criteria checks 0/6

Key information

Recent dividend updates

Recent updates

Founder notifies of intention to sell stock

Castle Biosciences, Inc. to Report Q1, 2024 Results on May 02, 2024

Castle Biosciences, Inc., Annual General Meeting, May 23, 2024

Independent Chairman of the Board notifies of intention to sell stock

Castle Biosciences, Inc. Announces Share New Data At the 20Th European Association of Dermato-Oncology Congress

Castle Biosciences, Inc. Announces Board Changes

Castle Biosciences, Inc. Announces the Publication of a New Multi-Center Performance Study of its DecisionDx-SCC Risk Stratification Test

Founder notifies of intention to sell stock

Consensus estimates of losses per share improve by 26%

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Castle Biosciences, Inc. Provides Revenue Guidance for the Full Year 2024

Castle Biosciences, Inc. to Report Second Half, 2023 Results on Feb 28, 2024

Independent Chairman of the Board notifies of intention to sell stock

Investors Appear Satisfied With Castle Biosciences, Inc.'s (NASDAQ:CSTL) Prospects

Castle Biosciences, Inc. Presents Data Supporting the Utility of Its Tests in the Clinical Care of Patients with Skin Cancers at the 2024 Winter Clinical Dermatology Conference - Hawaii

Castle Biosciences, Inc. Provides Revenue Guidance for the Year 2023

Forecast to breakeven in 2026

Founder exercised options and sold US$362k worth of stock

Independent Chairman of the Board notifies of intention to sell stock

Founder notifies of intention to sell stock

Castle Biosciences, Inc. Announces Data from A Single-Site, Open-Label Study Demonstrating the Consistent Impact of Idgenetix®? on Medication Response and Remission Rates in Patients with Major Depressive Disorder

Consensus estimates of losses per share improve by 21%

Castle Biosciences, Inc. Announces New Data Showing the Ability of Its Pipeline Test in Development to Distinguish Between Responders and Non-Responders to an Atopic Dermatitis

New minor risk - Shareholder dilution

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Castle Biosciences, Inc. Raises Earnings Guidance for the Full Year 2023

Castle Biosciences (NASDAQ:CSTL) Is In A Good Position To Deliver On Growth Plans

Castle Biosciences, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Castle Biosciences, Inc. Announces New Study Demonstrating DecisionDx-Melanoma Outperforms a Nomogram Developed at the Memorial Sloan Kettering Cancer Center

Castle Biosciences, Inc. Shares New Data Demonstrating Ability of TissueCypher Test Results to Inform Clinical Decision-Making in Patients with Non-Dysplastic Barrett's Esophagus

Castle Biosciences, Inc. Announces TissueCypher Barrett’s Esophagus Test Outperformed Standard of Care in Risk-Stratifying Patients with Barrett’s Esophagus

Castle Biosciences, Inc. Announces Data from a Study Showing the Addition of Drug-Drug Interactions and Lifestyle Factors to Drug-Gene Interactions

Consensus estimates of losses per share improve by 12%

Founder notifies of intention to sell stock

Castle Biosciences, Inc. Raises Revenue Guidance for the Full Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Independent Chairman of the Board notifies of intention to sell stock

Castle Biosciences to Present New DecisionDx®-Melanoma Data at the American Head & Neck Society's 11th International Conference on Head and Neck Cancer

Earnings Working Against Castle Biosciences, Inc.'s (NASDAQ:CSTL) Share Price Following 36% Dive

Castle Biosciences, Inc. Presents New Data Demonstrating the Ability of DecisionDx-SCC to Identify Tumors Likely to Metastasize in Patients with Cutaneous Squamous Cell Carcinoma Deemed Low Risk by Traditional Staging

Independent Director recently bought US$69k worth of stock

Price target decreased by 11% to US$39.75

Castle Biosciences, Inc. to Share New Data on DecisionDx-Melanoma and DecisionDx-UM at the 2023 ASCO Annual Meeting

Consensus EPS estimates fall by 16%, revenue upgraded

Founder notifies of intention to sell stock

Castle Biosciences, Inc. Reaffirms Revenue Guidance for the Full Year 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 11%, revenue upgraded

Full year 2022 earnings: EPS exceeds analyst expectations

Castle Biosciences, Inc. Publishes Data from Prospective, Multicenter Study, Called DECIDE

Castle Biosciences, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Founder notifies of intention to sell stock

Castle Biosciences, Inc. Revises Revenue Guidance for the for Full-Year 2022

Founder exercised options and sold US$141k worth of stock

Castle Biosciences Presents New Data Demonstrating the Clinical Utility and Value of DecisionDx®-SCC in Moderately and Poorly Differentiated Cutaneous Squamous Cell Carcinoma Tumors

Founder notifies of intention to sell stock

Founder notifies of intention to sell stock

Independent Chairman of the Board notifies of intention to sell stock

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Castle Biosciences, Inc. Revises Revenue Guidance for the Full Year 2022

Castle Biosciences, Inc. Presents New Data from Collaboration with the National Cancer Institute's (NCI) Surveillance, Epidemiology and End Results (SEER) Program

Castle Biosciences, Inc. Announces New Data Showing That the Use of Tissuecypher® Barrett’S Esophagus Test Results Can Significantly Improve Management Decisions for Barrett’S Esophagus (Be) Patients with Low-Grade Dysplasia (Lgd)To Improve Health Outcomes

Castle Biosciences, Inc. Announces New Data from Prospective, Multicenter DECIDE1 Study

Castle Biosciences, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Castle Biosciences, Inc. Announces Results from a Randomized Controlled Trial Show That TissueCypher® Barrett’s Esophagus Test Results Can Significantly Improve the Accuracy of Risk Assessments and Adherence to Guideline-Recommended Patient Management

Castle Biosciences, Inc. to Present Data Supporting the Clinical Value of Its Suite of Skin Cancer Tests through Multiple Oral Presentations at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting

Castle Biosciences Announces Publication of Study Demonstrating the Integration of DecisionDx(R)-Melanoma and Clinicopathologic Factors Provides Optimized, Survival Prognoses for Patients with Cutaneous Melanoma

Castle Biosciences, Inc. Presents Clinical Use Scenarios for Its Diagnostic Gene Expression Profile Tests At Maui Derm Np+Pa Fall 2022 Conference

Consensus revenue estimates increase by 10%

Analysts Just Published A Bright New Outlook For Castle Biosciences, Inc.'s (NASDAQ:CSTL)

Castle Biosciences, Inc. Revises Earnings Guidance for the Full Year 2022

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Castle Biosciences Q2 2022 Earnings Preview

Founder notifies of intention to sell stock